to advance its core technology products, Equivalent Announced a major upgrade to its Health Relationship Management (HRM) platform, an omnichannel SaaS product that helps healthcare organizations develop and maintain long-term customer relationships. These enhancements improve user experience, data collection, reporting, device tracking, and scalability.
“It is imperative for healthcare providers to move to a more customer-centric model,” says Equiva CEO Neil Altman“Our HRM environment connects data analytics with educational and behavioral science-driven approaches to purposefully mobilize intelligence-driven action among consumers, patients, their loved ones, and care team members.”
Equiva developed its HRM platform to help HCOs use digital engagement strategies more cohesively to strengthen relationships with existing patients and attract new clients. “We integrate unique aspects of patient engagement, care management and marketing capabilities into our digital environment, all within the framework of improving clinical and financial outcomes.”
Equiva tablets, mobile apps, kiosks, TVs, digital signage and remote patient monitoring solutions are deployed thousands of times by hundreds of leading healthcare organizations including Mount Sinai, Northwell, Providence, Hackensack, UNC Health and more to support the strategic plan.
To read more information, click here.
healthy mineThe company’s health risk assessment products have received Health and Health Promotion Certification in Health Assessment after rigorous scrutiny by the National Council for Quality Assurance (NCQA). This achievement is the result of Healthmine’s dedicated team of continuously optimizing its digital technology to meet NCQA’s high standards and provide clients with the best tools for collecting self-reported member data.
To read more information, click here.
digital health company Callum Health Metrics on patient outcomes and procedural appropriateness have been incorporated into its Center of Excellence (COE) platform. Carrum Health combines seven years of real-world patient outcomes data with comprehensive commercial claims, clinical and Medicare datasets, combined with a machine learning platform, to now provide unprecedented insights into the three most impactful aspects of quality Insights: Appropriateness, Functional Outcomes, and Traditional Readmission/Complication Indicators.
Carrum Health’s algorithm is the only quality tool on the market that considers appropriateness and patient-reported outcomes, while leveraging procedure-specific quality metrics developed by experts in each of its COE surgical and non-surgical specialties.
“As a physician, it’s important to work with organizations we share our commitment to high-quality patient care,” said Nicholas Theodore, MD, director of the Neurosurgical Spine Center and professor of neurosurgery at the Johns Hopkins University School of Medicine. “By measuring quality and appropriateness, Carrum Health sets higher standards by creating a measurement system and enabling patients to identify best-in-class providers. At the same time, it allows providers to focus on delivering care to patients who truly need it, ultimately driving better good result.”
nerve one, A medical technology company developing high-definition, minimally invasive thin-film electrodes for the diagnosis and treatment of neurological disorders has named a vice president of quality control and regulatory affairs.
Chad Wilhelmy was previously in HLT Medical, a subsidiary of Bracco Group.
To read more information, click here.
Prellis Biologics A multi-target drug discovery collaboration and licensing agreement has been signed with Bristol-Myers Squibb (BMS). According to the company, this is the first time a human-based antibody has been discovered in the pharmaceutical industry.
Prellis’ EXIS is the first fully synthetic, animal-free, functional human immune system that breaks tolerance mechanisms in vitro to generate high-affinity human antibodies against human proteins; advanced holographic printing technology can rapidly match and replicate the human body Organ and tissue structure. To date, Prellis has developed antibodies responsive to SARS-CoV-2, influenza A, and Marburg hemorrhagic fever.
Under the terms of the agreement, Prellis and BMS will collaborate to generate human antibody libraries for selected targets. Prellis will receive undisclosed upfront payments, funding for research activities, development and sales milestones, and royalties for licensed antibodies from BMS.
To read more information, click here.
picture: Arkindo, Getty Images
